ReviewBiomarker insights2024
Procalcitonin Guided Antibiotic Stewardship.
Review in Biomarker insights, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- A Prediction Score Versus Procalcitonin and Presepsin for Predicting Bacteremia in the Emergency Department: A Single-Center Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- The Role and Importance of Procalcitonin (PCT) Testing in Rational Antibiotic Prescribing and Antibiotic Stewardship Programs.Immunity, inflammation and disease · 2026Review
- Sepsis Biomarkers in Evolution: Comparative Insights and the Promising Roles of MDW and Presepsin.Medicina (Kaunas, Lithuania) · 2026Review
- Machine learning-based identification of inflammatory biomarkers for predicting pulmonary consolidation in children with Chlamydia pneumoniae infection.Frontiers in pediatrics · 2026Article
- Role of procalcitonin in identifying systemic inflammatory response syndrome and sepsis in acute-on-chronic liver failure and its impact on survival.BMC gastroenterology · 2025Article
- Bug Wars: Artificial Intelligence Strikes Back in Sepsis Management.Diagnostics (Basel, Switzerland) · 2025Review
- Clinical significance of C-reactive protein in patients with severe fever with thrombocytopenia syndrome.Journal of rural medicine : JRM · 2025Article
- The use and misuse of procalcitonin in the management of pneumonia: a retrospective analysis at a large tertiary care center.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite infection and sepsis being a major public health challenge, early detection and timely management are often hindered by several factors. These includes the similarity of clinical presentations between infectious and non-infectious conditisons, as well as limitations of current diagnostic methods such as lengthy turnaround times and low sensitivity. Consequently, there is increasing interest in identifying biomarkers that can quickly and accurately differentiate bacterial sepsis from other inflammatory processes, whether infectious or non-infectious. Procalcitonin has emerged as one of the most extensively studied and utilized biomarkers in managing infection and sepsis, especially within the framework of antibiotic stewardship. This review aims to examine the role of Procalcitonin in guiding antibiotic stewardship. It explores the production and release of procalcitonin and its relevance in the context of infection and sepsis. The discussion focus on the clinical and economic impacts of using procalcitonin to guide the initiation and discontinuation of antibiotics in managing these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.